$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

$kpti Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914002800 Filed on March 21, 2014

Income Statement

Concept	2014 Q1	2013	2012 Q4
Revenue	$171.0K	$387.0K	$33.00K
YoY Change	-26.61%	-38.96%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$5.900M	$610.0K
YoY Change	229.55%	145.83%
% of Gross Profit
Research & Development	$10.98M	$28.45M	$3.670M
YoY Change	121.13%	101.86%
% of Gross Profit
Depreciation & Amortization	$40.00K	$144.0K	$30.00K
YoY Change	33.33%	18.03%
% of Gross Profit
Operating Expenses	$13.88M	$34.34M	$4.271M
YoY Change	137.56%	107.8%
Operating Profit	-$13.71M	-$33.95M	-$4.238M
YoY Change	144.38%	113.66%
Interest Expense	$20.00K	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$18.00K	$3.000K
YoY Change		50.0%
Pretax Income	-$13.69M	-$33.90M	-$4.240M
YoY Change	144.03%	113.21%
Income Tax	$0.00	-$33.95M	$0.00
% Of Pretax Income
Net Earnings	-$13.69M	-$33.95M	-$4.240M
YoY Change	144.1%	113.66%
Net Earnings / Revenue	-8008.19%	-8771.83%	-12848.48%
Basic Earnings Per Share
Diluted Earnings Per Share	-$462.3K	-$5.557M	-$79.03K
COMMON SHARES
Basic Shares Outstanding	29.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.9M	$156.0M
YoY Change		38900.0%
Cash & Equivalents	$144.9M	$156.0M	$391.0K
Short-Term Investments
Other Short-Term Assets	$2.700M	$2.000M
YoY Change		233.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$147.6M	$158.0M	$954.0K
YoY Change		15700.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$322.0K	$200.0K	$327.0K
YoY Change		-33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$997.0K	$0.00	$30.00K
YoY Change
Total Long-Term Assets	$1.719M	$200.0K	$357.0K
YoY Change		-33.33%
TOTAL ASSETS
Total Short-Term Assets	$147.6M	$158.0M	$954.0K
Total Long-Term Assets	$1.719M	$200.0K	$357.0K
Total Assets	$149.3M	$158.2M	$1.311M
YoY Change		12069.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.273M	$1.700M	$1.076M
YoY Change		54.55%
Accrued Expenses	$1.550M	$1.200M	$764.0K
YoY Change		50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.015M	$3.300M	$1.930M
YoY Change		73.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$170.0K
YoY Change
Total Long-Term Liabilities	$170.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.015M	$3.300M	$1.930M
Total Long-Term Liabilities	$170.0K	$0.00
Total Liabilities	$5.185M	$3.300M
YoY Change		73.68%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$144.1M	$154.9M	-$27.88M
YoY Change
Total Liabilities & Shareholders Equity	$149.3M	$158.2M	$1.311M
YoY Change		12069.23%

Cashflow Statement

Concept	2014 Q1	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	-$13.69M	-$33.95M	-$4.240M
YoY Change	144.1%	113.66%
Depreciation, Depletion And Amortization	$40.00K	$144.0K	$30.00K
YoY Change	33.33%	18.03%
Cash From Operating Activities	-$10.57M	-$30.29M	-$3.980M
YoY Change	104.84%	95.29%
INVESTING ACTIVITIES
Capital Expenditures	$125.0K	$57.00K	$0.00
YoY Change		-52.89%
Acquisitions
YoY Change
Other Investing Activities	-$400.0K
YoY Change
Cash From Investing Activities	-$530.0K	-$60.00K	$0.00
YoY Change		-50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$113.2M
YoY Change		1257177.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	185.9M	2.500M
YoY Change	-99.82%	1855.1%
NET CHANGE
Cash From Operating Activities	-10.57M	-30.29M	-3.980M
Cash From Investing Activities	-530.0K	-60.00K	0.000
Cash From Financing Activities	10.00K	185.9M	2.500M
Net Change In Cash	-11.09M	155.6M	-1.480M
YoY Change	-3097.3%	-2642.16%
FREE CASH FLOW
Cash From Operating Activities	-$10.57M	-$30.29M	-$3.980M
Capital Expenditures	$125.0K	$57.00K	$0.00
Free Cash Flow	-$10.70M	-$30.35M	-$3.980M
YoY Change	107.27%	94.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Sales Revenue Net SalesRevenueNet	1266000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	200000	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	152000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	745000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	35000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29587258	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29587258	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2123388	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2123388	shares
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	387000	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	634000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28452000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14095000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8623000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52835000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5885000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2429000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1840000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10817000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	34337000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	16524000	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	10463000	USD
	us-gaap	Operating Expenses OperatingExpenses	63652000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-33950000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-15890000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-10311000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62386000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
	us-gaap	Interest Expense InterestExpense	188000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33947000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15888000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10311000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62569000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.59
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.95
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-35.00
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6067679	shares
CY2013	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-10922000	USD
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-23025000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1775323	shares
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1004144	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1787668	shares
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	350000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	144000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	122000	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	83000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1419000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	188000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	209000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	99000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	664000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-66000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1131000	USD
CY2013	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	382000	USD
CY2012	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	13000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	3785000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	653000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3445000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4508000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	24000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6512000	USD
	kpti	Noncash Consulting Expense NoncashConsultingExpense	788000	USD
CY2011	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	423000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	13000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-134000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	200000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30290000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15509000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8549000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	376000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-57000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-121000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-376000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	113155000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000	USD
CY2012	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2000000	USD
CY2011	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	6980000	USD
CY2013	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	72434000	USD
CY2012	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	7500000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1168000	USD
CY2011	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	5000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	185930000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9509000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11992000	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	155583000	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6121000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3067000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	750000	USD
	us-gaap	Notes Issued1 NotesIssued1	700000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1982000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1740000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	1170000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	79000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-55758000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	590000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-590000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	113177000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	70000	USD
	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	98754000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	212322000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	155974000	USD
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6800000	shares
CY2013Q4	us-gaap	Share Price SharePrice	16.00
CY2013Q4	kpti	Stock Issued During Period Shares New Issues To Be Made Upon Underwriters Exercise Of Option StockIssuedDuringPeriodSharesNewIssuesToBeMadeUponUnderwritersExerciseOfOption	1020000	shares
CY2013Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	113200000	USD
CY2013Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3030	pure
CY2013Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	19114241	shares
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	764000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2244000	USD
CY2013Q4	kpti	Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal	17876000	USD
CY2013	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P2Y
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	106000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	127000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	174000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155974000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1982000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	563000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	157956000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	954000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000	USD
CY2013Q4	us-gaap	Assets Assets	158226000	USD
CY2012Q4	us-gaap	Assets Assets	1311000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1740000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1076000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	79000	USD
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013Q2	dei	Entity Public Float EntityPublicFloat	0	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	66000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	305000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3292000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1930000	USD
CY2012Q4	kpti	Temporary Equity Subscriptions TemporaryEquitySubscriptions	8980000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	18278000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	62569000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	3669000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3635000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3635000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.37
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	34000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	98000	USD
CY2012Q4	kpti	Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal	10621000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	8000	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	133000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	7003000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6870000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6869000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.86
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	9321000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9321000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9321000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.66
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	21000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	12169000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-12148000	USD
CY2013Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12146000	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	533000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	4567000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4034000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4033000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
CY2012Q4	us-gaap	Sales Revenue Net SalesRevenueNet	33000	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	4271000	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4238000	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4238000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Use of Estimates</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        On an ongoing basis, the Company's management evaluates its estimates, including estimates related to clinical trial accruals, stock-based compensation expense, and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</font></p> </div>
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-15888000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33947000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15888000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	Karyopharm Therapeutics Inc.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001503802
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29753726	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158226000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1311000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	590000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	533000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	350000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	206000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	240000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	327000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	28622000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	154934000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-27877000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000	pure
CY2013	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	165000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	341000	USD
	kpti	Royalty And Sublicense Payment RoyaltyAndSublicensePayment	0	USD
CY2013Q4	kpti	Revenue Recognition Milestone Method Number Of Research Agreements RevenueRecognitionMilestoneMethodNumberOfResearchAgreements	2	item
CY2013Q4	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	698000	USD
CY2013	us-gaap	Depreciation Depreciation	144000	USD
CY2012	us-gaap	Depreciation Depreciation	122000	USD
	us-gaap	Depreciation Depreciation	350000	USD
CY2013	kpti	Number Of Wholly Owned Subsidiaries Requiring Consolidation NumberOfWhollyOwnedSubsidiariesRequiringConsolidation	2	item
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008	pure
CY2012Q4	kpti	Temporary Equity Subscriptions And Carrying Amount Attributable To Parent TemporaryEquitySubscriptionsAndCarryingAmountAttributableToParent	27258000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	341000	USD
CY2012	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	137000	USD
CY2010	kpti	Amount Of Federal Grant Awarded AmountOfFederalGrantAwarded	245000	USD
CY2010	kpti	Amount Of Federal Grant Received And Recognized In Income AmountOfFederalGrantReceivedAndRecognizedInIncome	93000	USD
CY2011	kpti	Amount Of Federal Grant Received And Recognized In Income AmountOfFederalGrantReceivedAndRecognizedInIncome	152000	USD
	kpti	Amount Of Federal Grant Received And Recognized In Income AmountOfFederalGrantReceivedAndRecognizedInIncome	245000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-2376000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	12000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-12651000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	100000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	302000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	155000	USD
CY2012Q4	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	333000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	215000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217500000	USD
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	18437500	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	00	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	30000	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	99691000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	99691000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-179000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-179000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	653000	USD
CY2013	kpti	Stock Issued During Period Value Conversion Of Convertible Preferred Securities StockIssuedDuringPeriodValueConversionOfConvertiblePreferredSecurities	99691000	USD
CY2013	kpti	Stock Issued During Period Value Conversion Of Special Participation Stock StockIssuedDuringPeriodValueConversionOfSpecialParticipationStock	88000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	5000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	113155000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3785000	USD
CY2011Q4	kpti	Stock Repurchase Program Number Of Closings StockRepurchaseProgramNumberOfClosings	2	item
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	233000	USD
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2011	us-gaap	Depreciation Depreciation	83000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	5844000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5611000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.52
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	34000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	4017000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	871000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3983000	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3982000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.71
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.08
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	2731000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2670000	USD
CY2013Q4	kpti	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences	1819000	USD
CY2012Q4	kpti	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences	335000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25096000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11827000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25096000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11827000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13300000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6200000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.052	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.039	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.029	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.391	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.391	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2013	kpti	Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered	P3Y
CY2013	kpti	Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered	0.50	pure
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2013Q4	kpti	Liability For Uncertain Tax Positions Current And Noncurrent LiabilityForUncertainTaxPositionsCurrentAndNoncurrent	0	USD
CY2013	kpti	Noncash Consulting Expense NoncashConsultingExpense	88000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	375000	USD
CY2012Q4	kpti	Liability For Uncertain Tax Positions Current And Noncurrent LiabilityForUncertainTaxPositionsCurrentAndNoncurrent	0	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	653000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3785000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4508000	USD
	us-gaap	Stock Issued1 StockIssued1	13980000	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	13980000	USD
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2012Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2011Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2013	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	418000	USD
CY2012	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	109000	USD
CY2011	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	889000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	1416000	USD

Files In Submission

Name	View Source	Status
0001047469-14-002800-index-headers.html	Edgar Link	pending
0001047469-14-002800-index.html	Edgar Link	pending
0001047469-14-002800.txt	Edgar Link	pending
0001047469-14-002800-xbrl.zip	Edgar Link	pending
a2218887z10-k.htm	Edgar Link	pending
a2218887zex-10_13.htm	Edgar Link	pending
a2218887zex-21_1.htm	Edgar Link	pending
a2218887zex-31_1.htm	Edgar Link	pending
a2218887zex-31_2.htm	Edgar Link	pending
a2218887zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g103044.jpg	Edgar Link	pending
g13617.jpg	Edgar Link	pending
g146011.jpg	Edgar Link	pending
g711212.jpg	Edgar Link	pending
kpti-20131231.xml	Edgar Link	completed
kpti-20131231.xsd	Edgar Link	pending
kpti-20131231_cal.xml	Edgar Link	unprocessable
kpti-20131231_def.xml	Edgar Link	unprocessable
kpti-20131231_lab.xml	Edgar Link	unprocessable
kpti-20131231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

2014 Q1 Form 10-K Financial Statement

#000104746914002800 Filed on March 21, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI Karyopharm Therapeutics Inc. Stock $kpti

2014 Q1 Form 10-K Financial Statement

#000104746914002800 Filed on March 21, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti